August 01, 2014 10:51 AM ET

Life Sciences Tools and Services

Company Overview of Cato Research Ltd.

Company Overview

Cato Research Ltd., a contract research and development organization, provides strategic and tactical support for pharmaceutical, biotechnology, and medical device industries in North America and internationally. The company offers services ranging from the design and management of preclinical and clinical studies to the submission of regulatory documents required for marketing approval. It also provides clinical trial, regulatory, medical and pharmacovigilance, nonclinical safety, data management and biostatistics, medical writing, quality assurance, project management, and investigator registry services; and chemistry, manufacturing, and control services. Cato Research Ltd. was founded in ...

4364 South Alston Avenue

Westpark Corporate Center

Durham, NC 27713-2220

United States

Founded in 1988





Key Executives for Cato Research Ltd.

Chief Financial Officer
Age: 58
Chief Legal Officer and Vice President of Corporate Development
Chief Operating Officer of CRSD
Compensation as of Fiscal Year 2014.

Cato Research Ltd. Key Developments

Pluristem Therapeutics, Inc. Selects Cato Research Ltd. as Contract Research Organization

Pluristem Therapeutics Inc. announced it has selected Cato Research Ltd. as its contract research organization (CRO) for the German portion of the company's phase II trial in intermittent claudication (IC) under the auspices of the Paul-Ehrlich Institute (PEI). Cato will serve as Pluristem's applicant for its IC Clinical Trial Application to the PEI and to the ethics committees of the three study sites where the trials will be conducted. The trial will evaluate the safety and efficacy of Pluristem's PLacental eXpanded (PLX-PAD) cells in treating IC, a subset of peripheral artery disease (PAD). The prevalence of IC in the United States alone is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system. In addition to Germany, Pluristem's multinational Phase II trial in IC will also include 11 sites in the United States and 2 sites in Israel with the US Food and Drug Administration (FDA) already approving the United States portion of this study. The trial will enroll 150 patients in a randomized, double blinded, placebo controlled study evaluating two doses of either 150 or 300 million PLX cells given intramuscularly three months apart. The primary endpoint of the trial will be maximum walking distance achieved on a treadmill at 12 months.

Similar Private Companies By Industry

Company Name Region
Balch Hill Medical, Inc. United States
American Medical Technologies, Inc. United States
Pierrel Research USA, Inc. United States
Biomatrica, Inc. United States
Aptuit LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cato Research Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at